These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 38359754)
1. 1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells. Zhao S; Ali AS; Liu X; Yu Z; Kong X; Zhang Y; Paul Savage G; Xu Y; Lin B; Wu D; Francis CL Bioorg Med Chem; 2024 Mar; 101():117634. PubMed ID: 38359754 [TBL] [Abstract][Full Text] [Related]
2. 1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells. Zhao S; Ali AS; Kong X; Zhang Y; Liu X; Skidmore MA; Forsyth CM; Savage GP; Wu D; Xu Y; Francis CL Eur J Med Chem; 2023 Jan; 246():114982. PubMed ID: 36495632 [TBL] [Abstract][Full Text] [Related]
3. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
4. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287 [TBL] [Abstract][Full Text] [Related]
5. Ginsenoside compound K suppresses tumour growth in the 22Rv1 xenograft model and inhibits androgenic responses via the transcriptional mechanism in human prostate cancer cells. Jiang M; Sun Y; Song K FEBS J; 2023 Apr; 290(7):1840-1854. PubMed ID: 36349420 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Singh KB; Ji X; Singh SV Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of androgen receptors by NaAsO Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958 [TBL] [Abstract][Full Text] [Related]
9. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107 [TBL] [Abstract][Full Text] [Related]
10. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer. Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630 [TBL] [Abstract][Full Text] [Related]
12. (+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist. Cole RN; Chen W; Pascal LE; Nelson JB; Wipf P; Wang Z Mol Cancer Ther; 2022 Apr; 21(4):483-492. PubMed ID: 35058329 [TBL] [Abstract][Full Text] [Related]
13. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer. Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511 [TBL] [Abstract][Full Text] [Related]
14. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer. Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864 [TBL] [Abstract][Full Text] [Related]
16. Antiandrogenic Effects of a Polyphenol in Kudo Y; Endo S; Tanio M; Saka T; Himura R; Abe N; Takeda M; Yamaguchi E; Yoshino Y; Arai Y; Kashiwagi H; Oyama M; Itoh A; Shiota M; Fujimoto N; Ikari A Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430833 [TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797 [TBL] [Abstract][Full Text] [Related]
18. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. Thamilselvan V; Menon M; Thamilselvan S Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552 [TBL] [Abstract][Full Text] [Related]
19. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Gaur S; Gross ME; Liao CP; Qian B; Shih JC Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539 [TBL] [Abstract][Full Text] [Related]
20. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]